Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications

information fournie par Boursorama CP •02/09/2026 à 18:00

TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer

Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responses

Together, the long-term clinical and translational data further strengthen confidence in Transgene’s individualized neoantigen therapeutic vaccine approach and myvac® platform


Strasbourg, France & Tokyo, Japan, September 2, 2026, 6:00 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, today report sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase 1 part of a randomized Phase 1/2 trial evaluating TG4050, the first individualized neoantigen therapeutic vaccine (INTV) based on the myvac® platform, in patients with resected, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

.../...